ID   NCC-ssRMS2-C1
AC   CVCL_A0BR
DR   Wikidata; Q108821015
RX   PubMed=34164773;
WW   https://en.cellline.jp/product/ncc-ssrms2-c1/
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo T.).
CC   Doubling time: ~41 hours (PubMed=34164773).
CC   Sequence variation: Mutation; HGNC; 7611; MYOD1; None_reported; -; Zygosity=- (PubMed=34164773).
CC   Omics: SNP array analysis.
CC   Misspelling: NCC-ssRMS1-C2; Note=In Cellosaurus release 39.
CC   Derived from site: In situ; Back; UBERON=UBERON_0001137.
ST   Source(s): PubMed=34164773
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 11
ST   D16S539: 9,11
ST   D21S11: 30,32.2
ST   D5S818: 10,11
ST   D7S820: 11
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 14,17
DI   NCIt; C121654; Spindle cell/sclerosing rhabdomyosarcoma
DI   ORDO; Orphanet_780; Rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   40Y
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 30-01-24; Version: 5
//
RX   PubMed=34164773; DOI=10.1007/s13577-021-00569-1;
RA   Tsuchiya R., Yoshimatsu Y., Noguchi R., Sin Y., Ono T., Sei A.,
RA   Takeshita F., Sugaya J., Nakatani F., Yoshida A., Ohtori S., Kawai A.,
RA   Kondo T.;
RT   "Establishment and characterization of NCC-ssRMS2-C1: a novel
RT   patient-derived cell line of spindle cell/sclerosing
RT   rhabdomyosarcoma.";
RL   Hum. Cell 34:1569-1578(2021).
//